Other compounds

LGD-4033: molecular data, studies & sources

LGD-4033 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C14H12F6N2O
Molecular weight (MW): 338.25 g/mol
PubChem compound ID: 44137686
Record title: Vk-5211

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 44137686 · retrieved 2026-10-09

2D molecular structure for LGD-4033, PubChem CID 44137686 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
InChIKey: OPSIVAKKLQRWKC-VXGBXAGGSA-N
SMILES: C1C[C@@H](N(C1)C2=CC(=C(C=C2)C#N)C(F)(F)F)[C@H](C(F)(F)F)O

Machine-readable PubChem source

Identifiers

PubChem CID: 44137686
CAS Registry Number: 1165910-22-4via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII: 1EJT54415A
ChEMBL ID: CHEMBL5170587
InChIKey: OPSIVAKKLQRWKC-VXGBXAGGSA-N
Wikidata: Q21098841

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-09.

Calculated molecular descriptors

Monoisotopic (exact) mass	338.0854 Da
Heavy atoms	23
Hydrogen-bond donors	1
Hydrogen-bond acceptors	3
Rotatable bonds	2
Topological polar surface area	47.3 Å²
Calculated logP (Crippen)	3.47
Rings	2
Stereocenters	2
Formal charge	0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

US regulatory status & drug development

Drug development record (ChEMBL)

Harmonized drug-development record from ChEMBL. The highest clinical stage is the furthest stage reached, as recorded by ChEMBL; it can lag regulatory approvals, and it is not an approval of a research-supplier product.

ChEMBL ID: CHEMBL5170587
Modality: Small molecule
Highest clinical stage: Phase 2
Record name: VK5211

Mechanism of action

Androgen Receptor modulator · target: Androgen receptor (AR)

Synonyms, codes and trade names

Synonyms and development codes: LGD-4033

Identity check: Identical standard InChIKey to the PubChem record. Source: ChEMBL CHEMBL5170587 (EMBL-EBI, CC BY-SA 3.0) · retrieved 2026-10-09

Registered clinical trials

Studies registered on ClinicalTrials.gov that list LGD-4033 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

1 registered study matched, 1 with results posted on ClinicalTrials.gov.

By highest phase: Phase 2 · 1
By registry status: Completed · 1

Study	Phase · status	Conditions	Sponsor · size
Acute Hip Fracture Study in Patients 65 Years or GreaterNCT02578095 · start 2015-10-30 · primary completion 2017-11-15	Phase 2CompletedResults posted 2025-12-29	Hip Fractures	Viking Therapeutics, Inc.108 participants

Registry check 2026-10-09 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received LGD-4033, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

Human study · PubMed trial index Compound given to participants
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.
Basaria S, Collins L, Dillon EL et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2012
PMID 22459616 · DOI: 10.1093/gerona/gls078

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Preclinical / laboratory research
Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model.
Roch PJ, Henkies D, Carstens JC et al. · Frontiers in endocrinology · 2020
PMID 33042018 · DOI: 10.3389/fendo.2020.556581
Research publication · design requires review
Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples Detected with or without Other Xenobiotics.
Kwiatkowska D, Wicka M, Grucza K et al. · Molecules (Basel, Switzerland) · 2023
PMID 37764261 · DOI: 10.3390/molecules28186486
Case report
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report.
Cardaci TD, Machek SB, Wilburn DT et al. · Experimental physiology · 2022
PMID 36303408 · DOI: 10.1113/EP090741
Research publication · design requires review
Human in vivo metabolism study of LGD-4033.
Fragkaki AG, Sakellariou P, Kiousi P et al. · Drug testing and analysis · 2018
PMID 30255601 · DOI: 10.1002/dta.2512
Research publication · design requires review
Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis.
Hoffmann DB, Derout C, Müller-Reiter M et al. · Journal of bone and mineral metabolism · 2023
PMID 37407738 · DOI: 10.1007/s00774-023-01453-8
Preclinical / laboratory research
Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration.
Sugumar D, Ghosh R, Rymbai E et al. · Assay and drug development technologies · 2024
PMID 39501873 · DOI: 10.1089/adt.2024.029
Research publication · design requires review
Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes.
Wagener F, Guddat S, Görgens C et al. · Analytical and bioanalytical chemistry · 2021
PMID 34734312 · DOI: 10.1007/s00216-021-03740-7

LGD-4033 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

PubChem compound record 44137686 — chemical identity and structure.
ChEMBL drug record CHEMBL5170587 — development stage, mechanism and synonyms.
FDA Global Substance Registration System: UNII 1EJT54415A — substance identity, names and codes.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.